瑞戈非尼治疗血管肉瘤的开放标签单臂II期研究
该单臂多中心开放标签II期研究纳入31例转移性或局部晚期不可切除血管肉瘤患者,接受瑞戈非尼160mg口服每日一次,连用21天/28天周期。主要终点为4个月无进展生存率,23例可评估患者中总缓解率17.4%,中位PFS 5.5个月,52.2%患者PFS超过4个月,32.3%可评估毒性患者出现≥3级不良事件。
要点
- 瑞戈非尼在经治转移性或不可切除血管肉瘤中显示抗肿瘤活性,总缓解率17.4%。
- 中位PFS为5.5个月,52.2%可评估患者PFS超过4个月。
- 32.3%可评估毒性患者出现≥3级不良事件,安全性与其他肿瘤研究相当。
核心结论
- 瑞戈非尼是转移性或不可切除血管肉瘤的安全且有效的治疗选择。
- 单药瑞戈非尼可考虑用于转移性或不可切除血管肉瘤患者的治疗。
研究设计与样本
- 单臂多中心开放标签II期临床试验,纳入31例转移性或局部晚期不可切除血管肉瘤患者。
- 患者年龄≥18岁,ECOG评分0-1,预期生存至少4个月,既往接受过至少1线但不超过4线治疗后进展。
- 瑞戈非尼160mg口服每日一次,连用21天,每28天为一个周期。
- 主要终点为4个月无进展生存率,次要终点包括总生存期、缓解率和安全性。
主要发现
- 23例可评估疗效患者中,2例完全缓解(8.7%),2例部分缓解(8.7%),总缓解率17.4%。
- 中位无进展生存期为5.5个月,12/23例(52.2%)患者无进展生存期超过4个月。
- 31例可评估毒性患者中,10例(32.3%)出现≥3级不良事件。
临床怎么用
- 对于既往治疗失败的转移性或不可切除血管肉瘤患者,可考虑使用瑞戈非尼单药治疗。
- 治疗期间需监测不良事件,≥3级不良事件发生率为32.3%。
局限性
- 单臂设计,无对照组,样本量较小(31例),疗效评估仅23例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Angiosarcomas represents a diverse group of aggressive high-grade vascular tumours with limited therapeutic options. We sought to determine the safety and efficacy of regorafenib, a small-molecule multikinase inhibitor, in the treatment of metastatic or locally advanced unresectable angiosarcoma. PATIENTS AND METHODS: In this single-arm multicentre, open-label phase II clinical trial, 31 patients were enrolled and received regorafenib 160 mg PO daily for 21 days of a 28-day cycle. The primary endpoint for the study was progression-free survival at 4 months. Secondary endpoints included overall survival, response rate, and safety. Patients (≥18 years) with an Eastern Cooperative Oncology Group (ECOG) score of 0-1, a life expectancy of at least 4 months who had progressed on at least one but no more than 4 prior lines of therapy were eligible. RESULTS: Of the 23 patients evaluable for efficacy, 2 had a complete response (8.7%), and 2 had a partial response (8.7%), for a total overall response rate of 17.4%. Median PFS was 5.5 months, and 12/23 patients (52.2%) had a PFS of greater than 4 months. 10/31 (32.3%) patients evaluable for toxicity had a grade 3 or higher adverse events. CONCLUSIONS: Regorafenib is a safe and active treatment for refractory metastatic and unresectable angiosarcoma. Rates of adverse events were comparable to prior studies of regorafenib for other tumour types. Regorafenib, the single agent, could be considered as therapy for patients with metastatic or unresectable AS.
引用
- Agulnik M, Schulte B, Robinson S, et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021. PMID: 34284255. doi:10.1016/j.ejca.2021.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。